BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
|
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [11] Efficacy and tolerability of fremanezumab for migraine preventive treatment in Korean patients with chronic or episodic migraine
    Kim, Byung-Kun
    Cohen, Joshua
    Kim, Sukyung
    Chang, Daeho
    Ning, Xiaoping
    Lengil, Tamar
    Janka, Lindsay
    Barash, Steve
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 214 - 214
  • [12] Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States
    Varnado, Oralee J.
    Ye, Wenyu
    Mi, Xiaojuan
    Burge, Russel
    Hall, Jerry
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 149 - 157
  • [13] Monoclonal antibodies for preventive treatment of episodic and chronic migraine
    Bigal, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E459 - E460
  • [14] Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Zhang, Qi
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [15] Galcanezumab Safety/tolerability Profile Does Not Differ in Patients with Episodic or Chronic Migraine
    Stauffer, V
    Wang, S.
    Day, K.
    Saper, J. R.
    HEADACHE, 2019, 59 : 45 - 46
  • [16] Efficacy and safety of different doses of subcutaneous galcanezumab in chronic and episodic migraine: A pooled analysis of 3651 patients
    Zaazouee, Mohamed Sayed
    Elsnhory, Ahmed
    Ebrahim, Rokaya Y.
    Al-araj, Ghaida'a
    Saad, Ahmed
    Zaki, Ibram
    Ali, Mustafa Hussein
    Fawy, Omar Khaled Fahmy
    Ahmed, Hadi F.
    Elshennawy, Mohamed
    Eleyan, Mohammed
    Alahmad, Ziad
    Hamra, Reem I. Abo
    AbuEl-Enien, Hazem
    Elromely, Rasha Abdo
    Elshanbary, Alaa Ahmed
    NEUROLOGY, 2023, 100 (17)
  • [17] Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
    Irimia, Pablo
    Santos-Lasaosa, Sonia
    Pozo-Rosich, Patricia
    Leira, Rogelio
    Pascual, Julio
    Lainez, Jose Miguel
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [18] Efficacy of Galcanezumab in Patients with Episodic Cluster Headaches and a History of Preventive Treatment Failure
    Plato, B. M.
    Andrews, J.
    Rettiganti, M.
    Tockhorn-Heidenreich, A.
    Bardos, J.
    Wenzel, R.
    Kuruppu, D.
    Ambrosini, A.
    HEADACHE, 2020, 60 : 53 - 54
  • [19] Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
    Kim, Byung-Kun
    Cho, Soo-Jin
    Han, Jeong Hee
    Dell'Agnello, Grazia
    Panni, Tommaso
    Kim, Manho
    Oh, Kyungmi
    Moon, Heui-Soo
    Chu, Min Kyung
    JOURNAL OF CLINICAL NEUROLOGY, 2023, 19 (05): : 483 - 494
  • [20] Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Michael Ament
    Kathleen Day
    Virginia L. Stauffer
    Vladimir Skljarevski
    Mallikarjuna Rettiganti
    Eric Pearlman
    Sheena K. Aurora
    The Journal of Headache and Pain, 2021, 22
12345